Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

NCT06830629 is registered in ClinicalTrials.gov with Maze Therapeutics as lead sponsor.

NCT NCT06830629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06830629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
Lead sponsor
Maze Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
February 5, 2025
Completion date
September 30, 2026
Enrollment
74 (estimated)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

proteinuric kidney disease